Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve α-adrenoceptors

British Journal of Pharmacology

Volumn 147, Issue 8, 2006, Pages 926-934

  Bexis, Sotiria ^a   Docherty, James R ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

1 adrenoceptors; 2A adrenoceptors; BRL 44408; Hyperthermia; Hypothermia; MDA; MDEA; MDMA; Rat aorta; Rat vas deferens

Indexed keywords

2 (1 METHYL 2 ISOINDOLINYLMETHYL) 2 IMIDAZOLINE; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALPHA 1A ADRENERGIC RECEPTOR; ALPHA 1D ADRENERGIC RECEPTOR; ALPHA 2A ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; N ETHYL 3,4 METHYLENEDIOXYAMPHETAMINE; PRAZOSIN; RADIOLIGAND; TRITIUM; YOHIMBINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; BRADYCARDIA; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; CORE TEMPERATURE; DIASTOLIC BLOOD PRESSURE; DRUG POTENCY; DRUG RECEPTOR BINDING; HEART RATE; HYPOTHERMIA; LOCOMOTION; MALE; MEAN ARTERIAL PRESSURE; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; RAT; SUBSTANCE ABUSE; SYSTOLIC BLOOD PRESSURE; TELEMETRY; THERMOREGULATION; VAS DEFERENS;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; AORTA; BLOOD PRESSURE; BODY TEMPERATURE; HEART RATE; IMIDAZOLES; INDOLES; ISOINDOLES; MALE; MOTOR ACTIVITY; MUSCLE CONTRACTION; MUSCLE, SMOOTH; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA; TIME FACTORS; VAS DEFERENS;

EID: 33646567449     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706688     Document Type: Article

References (46)

1. AL-SAHLI, W., AHMAD, H., KHERADMAND, F., CONNOLLY, C. & DOCHERTY, J.R. (2001). Effects of methylenedioxymethamphetamine on noradrenaline-evoked contractions of rat right ventricle and small mesenteric artery. Eur. J. Pharmacol., 422, 169-174.
2. ARRUE, A., GOMEZ, F.M. & GIRALT, M.T. (2004). Effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') on the jaw-opening reflex and on the alpha-adrenoceptors which regulate this reflex in the anesthetized rat. Eur. J. Oral. Sci., 112, 127-133.
3. BADON, L.A., HICKS, A., LORD, K., OGDEN, B.A., MELEG-SMITH, S. & VARNER, K.J. (2002). Changes in the cardiovascular responsiveness and cardiotoxicity elicited during binge administration of ecstasy. J. Pharmacol. Exp. Ther., 302, 898-907.
4. BANKSON, M.G. & CUNNINGHAM, K.A. (2001). 3,4- Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions. J. Pharmacol. Exp. Ther., 297, 846-852.
5. BARHAM, H.M., LENNARD, M.S. & TUCKER, G.T. (1994). An evaluation of cytochrome P450 isoform activities in the female dark agouti (DA) rat: relevance to its use as a model of the CYP2D6 poor metaboliser phenotype. Biochem. Pharmacol., 47, 1295-1307.
6. 2A- adrenoceptors in the effects of MDMA on body temperature in the mouse. Br. J. Pharmacol., 146, 1-6.
7. BOULES, M., WARRINGTON, L., FAUQ, A., MCCORMICK, D. & RICHELSON, E. (2001). A novel neurotensin analog blocks cocaine-and D-amphetamine-induced hyperactivity. Eur. J. Pharmacol., 426, 73-76.
8. 50) of an enzymatic reaction. Biochem. Pharmacol., 22, 3099-3108.
9. CLEARY, L., BUBER, R. & DOCHERTY, J.R. (2002). Effects of amphetamine derivatives and cathinone on noradrenaline-evoked contractions of rat right ventricle. Eur. J. Pharmacol., 451, 303-308.
10. CLEARY, L. & DOCHERTY, J.R. (2003). Actions of amphetamine derivatives and cathinone at the noradrenaline transporter. Eur. J. Pharmacol., 476, 31-34.
11. COLADO, M.I., GRANADOS, R., O'SHEA, E., ESTEBAN, B. & GREEN, R. (1999). The acute effects in rats of 3,4-methylenedioxyethamphetamine (MDEA, 'Eve') on body temperature and long term degeneration of 5HT neurones in brain: a comparison with MDMA ('Ecstasy'). Pharmacol. Toxicol., 84, 261-266.
12. COLADO, M.I., WILLIAMS, J.L. & GREEN, R. (1995). The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br. J. Pharmacol., 115, 1281-1289.
13. COLE, J.C. & SUMNALL, H.R. (2003a). Altered states: the clinical effects of Ecstasy. Pharmacol. Ther., 98, 35-58.
14. COLE, J.C. & SUMNALL, H.R. (2003b). The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA). Neurosci. Biobehav. Rev., 27, 199-217.
15. CONNAUGHTON, S. & DOCHERTY, J.R. (1990). Functional evidence for heterogeneity of peripheral prejunctional alpha2-adrenoceptors. Br. J. Pharmacol., 101, 285-290.
16. CRYAN, J.F., HARKIN, A., NAUGHTON, M., KELLY, J.P. & LEONARD, B.E. (2000). Characterization of D-fenfluramine-induced hypothermia: evidence for multiple sites of action. Eur. J. Pharmacol., 390, 275-285.
17. DAWS, L.C., IRVINE, R.J., CALLAGHAN, P.D., TOOP, N.P., WHITE, J.M. & BOCHNER, F. (2000). Differential behavioral and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog. Neuro-Psychopharmacol. Bio. Psychiat., 24, 955-977.
18. DE LA TORRE, R., FARRE, M., ORTUNO, J., MAS, M., BRENNEISEN, R., ROSET, P.N., SEGURA, J. & CAMI, J. (2000). Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. Br. J. Clin. Pharmacol., 49, 104-109.
19. 2-adrenoceptors. Eur. J. Pharmacol., 361, 1-15.
20. ENSSLIN, H.K., MAURER, H.H., GOUZOULIS, E., HERMLE, L. & KOVAR, K.A. (1996). Metabolism of racemic 3,4-methylenedioxyethylamphetamine in humans. Isolation, identification, quantification, and synthesis of urinary metabolites. Drug Metab. Dispos., 24, 813-820.
21. FITZGERALD, J.L. & REID, J.J. (1994). Sympathomimetic actions of methylenedioxymethamphetamine in rat and rabbit isolated cardiovascular tissues. J. Pharm. Pharmacol., 46, 826-832.
22. FOLTIN, R.W. & SCHUSTER, C.R. (1982). Behavioral tolerance and cross-tolerance to dl-cathinone and d-amphetamine in rats. J. Pharmacol. Exp. Ther., 222, 126-131.
23. GHURAN, A., VAN DER WIEKEN, L.R. & NOLAN, J. (2001). Cardiovascular complications of recreational drugs. Br. Med. J., 323, 464-466.
24. GOLD, L.H., KOOB, G.K. & GEYER, M.A. (1988). Stimulant and hallucinogenic behavioural profiles of 3,4-methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. J. Pharmacol. Exp. Ther., 247, 547-555.
25. GOUZOULIS, E., VON BARDELEBEN, U., RUPP, A., KOVAR, K.-A. & HERMLE, L 1993. Neuroendocrine and cardiovascular effects of MDE in healthy volunteers. Neuropsychopharmacology, 8, 187-193.
26. GUIMARAES, S. & MOURA, D. (2001). Vascular adrenoceptors: an update. Pharmacol. Rev., 53, 319-356.
27. HAYNER, G.N. & MCKINNEY, H. (1986). MDMA, the dark side of Ecstasy. J. Psychoactive Drugs, 18, 341-347.
28. HEGADOREN, K.M., BAKER, G.B. & BOURIN, M. (1999). 3,4-Methylenedioxy analogues of amphetamine: defining the risk to humans. Neurosci. Behav. Rev., 23, 539-553.
29. KALIVAS, P.W., DUFFY, P. & WHITE, S.R. (1998). MDMA elicits behavioral and neurochemical sensitization in rats. Neuropsychopharmacology, 18, 469-479.
30. LAHDESMAKI, J., SALLINEN, J., MACDONALD, E., SIRVIO, J. & SCHEININ, M. (2003). Alpha2-adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the alpha2A-adrenoceptor subtype. Neuropharmacology, 44, 882-892.
31. 2-adrenoceptor mediated actions of MDMA in rat atrium and vas deferens. Br. J. Pharmacol., 128, 975-980.
32. MALBERG, J.E. & SEIDEN, L.S. (1998). Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J. Neurosci., 18, 5086-5094.
33. MALPASS, A., WHITE, J.M., IRVINE, R.J., SOMOGYI, A.A. & BOCHNER, F. (1999). Acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA) in Sprague-Dawley and dark Agouti rats. Pharmacol. Biochem. Behav., 64, 29-34.
34. MCCANN, U.D., SLATE, S.O. & RICAURTE, G.A. (1996). Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; 'Ecstasy'). Drug Safety, 15, 107-115.
35. 2-adrenoceptors in the anaesthetized rat. Br. J. Pharmacol., 133, 429-437.
36. O'CAIN, P.A., HLETKO, S.B., OGDEN, B.A. & VARNER, K.J. (2000). Cardiovascular and sympathetic responses and reflex changes elicited by MDMA. Physiol. Behav., 70, 141-148.
37. O'LOINSIGH, E.D., BOLAND, G., KELLY, J.P. & O'BOYLE, K.M. (2001). Behavioural, hyperthermic and neurotoxic effects of 3,4- methylenedioxymethamphetamine anologues in the Wistar rat. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 25, 621-638.
38. PEDERSEN, N.P. & BLESSING, W.W. (2001). Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (Ecstasy) in conscious rabbits. J. Neurosci., 21, 8648-8654.
39. SPRAGUE, J.E., BRUTCHER, R.E., MILLS, E.M., CADEN, D. & RUSYNIAK, D.E. (2004). Attenuation of 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-induced rhabdomyolysis with α1 plus β3-adrenoceptor antagonists. Br. J. Pharmacol., 142, 667-670.
40. STUERENBURG, H.J., PETERSEN, K., BAUMER, T., ROSENKRANZ, M., BUHMANN, C. & THOMASIUS, R. (2002). Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users. Neuro. Endocrinol. Lett., 23, 259-261.
41. SUGIMOTO, Y., OHKURA, M., INOUE, K. & YAMADA, J. (2000). Involvement of the 5-HT(2) receptor in hyperthermia induced by p-chloroamphetamine, a serotonin-releasing drug in mice. Eur. J. Pharmacol., 403, 225-228.
42. SUGIMOTO, Y., OHKURA, M., INOUE, K. & YAMADA, J. (2001). Involvement of serotonergic and dopaminergic mechanisms in hyperthermia induced by a serotonin-releasing drug, p-chloroamphetamine in mice. Eur. J. Pharmacol., 430, 265-268.
43. VANDEPUTTE, C. & DOCHERTY, J.R. (2002). Vascular actions of 3,4-methylenedioxymethamphetamine in alpha2A/D-adrenocepor knockout mice. Eur. J. Pharmacol., 457, 45-49.
44. VOLLENWEIDER, F.X., GAMMA, A., LIECHTI, M. & HUBER, T. (1998). Psychological and cardiovascular effects and short-term sequelae of MDMA ('Ecstasy') in MDMA-naïve healthy volunteers. Neuropsychopharmacology, 19, 241-251.
45. YOUNG, P., BERGE, J., CHAPMAN, H. & CAWTHORNE, M.A. (1989). Novel alpha 2-adrenoceptor antagonists show selectivity for alpha 2A- and alpha 2B-adrenoceptor subtypes. Eur. J. Pharmacol., 168, 381-386.
46. ZARRINDAST, M.-R., SADEGHI, S. & SAHEBGHARANI, M. (2003). Influence of α-adrenoceptor agonists and antagonists on imipramine-induced hypothermia in mice. Pharmacol. Toxicol., 93, 48-53.